Imitrex Patent Settlement Allows For Entry During Pediatric Exclusivity Period
This article was originally published in The Pink Sheet Daily
Executive Summary
Spectrum/Par say launch of subcutaneous sumatriptan could come as early as Aug. 6, 2008.
You may also be interested in...
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.
Pozen/GlaxoSmithKline’s Trexima Gets Second FDA Approvable Letter
Pozen plans to pursue additional toxicity studies suggested by FDA.